Development of new antituberculosis agents;Desarrollo de nuevos agentes antituberculosos

Enfermedades Emergentes

Volumn 7, Issue 1, 2005, Pages 22-33

  Del Olmo Fernández, Esther ^a   López Pérez, José Luís ^a   San Feliciano, Arturo ^a   García, Ana Esther ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Anti tubercular drugs; Drug action mechanism; Enzyme inhibitors design; MDR TB; Mycolic acids; Natural products; Tuberculosis

Indexed keywords

12 NORMILTICAULINE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DITERPENE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN B; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; NITROIMIDAZOLE DERIVATIVE; NITROIMIDAZOXAZINE DERIVATIVE; OFLOXACIN; OXAZOLIDINE DERIVATIVE; PA 1343; PHENAZINE DERIVATIVE; PURINE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIADIAZINE DERIVATIVE; THIOLACTOMYCIN; TRIPTANTRIN; TUBERCULOSTATIC AGENT; U 100480; U 101244; U 101603; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; COMMUNITY CARE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; GENE ISOLATION; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PATHOGENESIS; TUBERCULOSIS;

EID: 17644367810     PISSN: 15754723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. World Health Organization. WHO Report 2001.
2. World Health Organization. Tuberculosis Fact Sheet, No. 104. 2000, http://www.who.int/int-fs/en/fact104.html/.
3. Farmer P, Bayona J, Beccera M, et al. The dielemma of MDR TB in global era. Int J Tuberc Lung Dis 1998;2:869-76
4. McKinney JD, Honer zu Bentrup K, Muñoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requiere the glyoxylate shunt enzyme isocytrate lyase. Nature 2000;406:735-8.
5. Dony JF, Ahmad J, Khen Tiong Y. Epidemiology of tuberculosis and leprosy, Sabah, Malaysia. Tuberculosis 2004;84:8-18
6. World Health Organization. Strategic framework to decrease the burden of TB/HIV document WHO/CDS/TB2002, 296, WHI/HIV AIDS/2002,2. Geneva, Switzerland World Health Organization; 2002.
7. World Health Organization, 2002. Global tuberculosis. Doc. WHO/CDS/TB/2000.275.
8. Piatek AS, Tyagi S, Pol AC , et al. Molecular beacon sequence analysis: A novel approach to the detection of drug resistance in Mycobacterium tuberculosis. Nat Biotech 1998;16:359-63.
9. Crofton JO, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. Geneva: World Health Organization; 1997. Also available from: URI: http://www.who.int/gtb/publication/gmdrt/.
10. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
11. Ainsa JA, Perez E, Pelicic V, et al. Aminoglycoside 20-N- acetyltransferase genes are universally present in Mycobacteria: Characterization of the aac(20)-Ic gene from Mycobactsrium tuberculosis and the aac (20)Id gene from Mycobacterium smegmatis. Mol Microbiol 1997;24:431-41.
12. Bush K, Miller GH. Bacterial enzymatic resistance: β-lactamases and aminoglycoside modifying enzymes. Curr Opinion Microbiol 1998;1:509-15.
13. Rose DN. Short course prophylaxis against tuberculosis in HIV infected persons: A decision and cost-effective analysis. Ann Intern Med 1998;129:779-86.
14. Heym B, Honore N, Schurra C, et al. Implications of multidrug resistance for the future of short source chemotherapy of tuberculosis: A molecular study. Lancet 1994;344:293-8.
15. Cooler RN, Campos Neto A, Ovendale P, et al. Vaccination with T cell antigen Mtb 8.4 protects against challenge with M. tuberculosis. J Immunol 2001;166:6227-35.
16. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of M. tuberculosis. Infect Immun 1999;67:1702-7.
17. Olsen AW, Pinxteren LAH, Okkels LM, Rasmussen PB, Anderson P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Med Immun 2001;69:2773- 8.
18. Nor NM, Musa M. Approaches towards the development of a vaccine against tuberculosis: Recombinant BCG and DNA vaccine. Tuberculosis (Edinb) 2004;84:102-9.
19. Murthy KJR, Lakshmi W, Singh S, Vijai Lkashmi V. Role of immunotherapy in the treatment of tuberculosis. Ind J Clin Biochem 1997;12(Suppl):76-9.
20. Stanford JL, Rook GA, Bahr GM, et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990;8(6):525-30.
21. Dalgleish AG. Immunotherapy with Mycobacterium vaccae. Lancet 1999;354:1338-1339.
22. Tillotson GS, Tuberculosis: New aspects of chemoterapy. J. Med. Microbiol. 1996;44: 16-20.
23. Greenwood D. Historical introduction. In: O'Grady F, Lambert HP, Finch RG, Greenwood D, editors. Antibiotic and chemotherapy, 7th edition. Edinburg: Churchill Livingston; 1997. pp 2-9.
24. Mieissner G. The bacteriology of the tubercular baccilus. In: Barry BC, editor. Chemotherapy of tuberculosis. London: Butterworths; 1964.
25. Sreevatsan S, Pan Xi, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indictes evolutionary recent global dissemination. Proc Natl Acad Sci USA 1997;94:9869-74.
26. Bosch R, Gordon SV, Billault A, et al. Use of Mycobacterium tuberculosis H37 Rv bacterial artificial chromosome library for genome mapping, sequencing and comparative genomics. Infect Immun 1998;66:2221-9.
27. Davidson PT, Le HQ. Drug treatment of tuberculosis-1992. Drugs 1992;43:651-73.
28. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996;65:215-39.
29. Zhang Y, Garbe T, Young D. Transformation with katG restores isoniazid-senstivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1993;8:521-524.
30. Jhonson K, Schultz PG. Mechanistic studies of the oxidation of INH by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994;116:7425-6.
31. Chopra I, Brennan P. Molecular action of antimycobacterial agents. Tuber Lung Dis 1998;78(2):89-98.
32. Parneti F, Lancini G. Rifamycins. In: O'Grady F, Lambert HP, Finch RG, Greenwood D, editors. Antibiotic and chemotherapy, 7th edition. Edinburg: Churchill Livingston; 1997. pp 453-9.
33. Saito H, Tomioka H, Sato K, et al. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents Chemother 1991;35:542-47.
34. Robin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657 and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003;47(3):1135-6.
35. Tomioka H. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Arch Immunol Ther Exp (Warsz) 2000;48(3):183-8.
36. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:1-6.
37. Konno K, Feldmann FM, Mc Dermott W. Pyrazinamide suceptibility and amidase activity of tubercular bacilli. Am Rev Resp Dis 1967;95:461-9.
38. Mc Dermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am Rev Tuberculosis 1954;70:748-54.
39. Cyanamon MH, Klemmens SP. Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem 1982;35:1212-15.
40. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifamycin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991;35:462-70.
41. Mikusova K, Slayeden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995;39:2484-89.
42. Lee RE, Mikusova K, Brennan PJ, Besra GS. Synthesis of the mycobacterial arabinose donar β-D-arabinosyl-1-monophosphoryldecaprenol, development of basic arabinosyl trasferase assay and identification of ethambutol arabinosyl transferase inhibitor. J Am Chem Soc 1995;117:11829-32.
43. Offe HA. Historical introduction and chemical characteristics of antituberculosis drugs. In: Bartmann K, editor. Antituberculosis drugs, handbook of experimental pharmacology, Vol. 84. Berlin: Springer-Verlag; 1988. pp 1-30.
44. Trinka L, Mison P. Drugs and treatment regimens, 1. ρ-aminosalicylic acid (PAS). In: Bartmann K, editor. Antituberculosis drugs, handbook of experimental pharmacology, Vol. 84. Berlin: Springer-Verlag; 1988. pp 51-68.
45. Otten H. Experimental evaluation of efficacy VII. Cycloserine (CS) and terizidone (TZ). In: Bartman K, editor. Antituberculosis drugs. Handbook of experimental pharmacology, Vol. 44, Berlin: Springer Verlag; 1988. pp 158-66.
46. Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ. The molecular basic of antibiotic action, 2nd edition. London: John Wiley and Sons; 1981.
47. Tumbanatham A, Vinodkumar S. Ofloxacin induced arthropathy in patients with multidrug resistance tuberculosis. J Assoc Physicians India 2000;48(6):647-8.
48. Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanism of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemotherp 1985;28:581-6.
49. Ashtekar DR, Fernandez F, Khadse GG, Shirodkar MVN. A rapid method for the evaluation of new antituberculosis agentes. Chemotherapy, (Basel, Switzerland) 1987;33:22-7.
50. Cheng GAC, Aktar Z, Jackson S, Ducan K. High-throughput screen for detecting antimycobacterial agents. Antimicrob. Agents Chemother. 1995;39:2235-8.
51. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997;41:1004-9.
52. Heifets LB. Qualitative and quantitative drugs-susceptibility tests in mycobacteriology. Am. Rev. Respir. Dis. 1988;137:1217-22.
53. Kremer L, Douglas JD, Morehouse C, et al. Thiolactomycin and related analogs as novel antimycobacteriai agents targeting Kas A and Kas B condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 200O;275:l6857.
54. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124(4):1482-1786.
55. Agrawal KC, Bears KB, Sehgal RK. Potential radiosenstizing agents dinitroimidazoies. J Med Chem 1979;22:583-6.
56. Nagarjan K, Shumker RG, Rajjapa S, Shenoy SJ, Costa-Perira R. Nitroimidazoles XXI-2,3-Dihydro-6nitroimidazo[2,1-b] oxazoles with antitubercular activity. Eur J MedChem 1989;24:631-3.
57. Wayne LG, Sramak HA. Nitroimidazole is bactericidal to dormnant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054.
58. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitraimidazoles CGI 17341 against Mycobacterium against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993;37:183-6.
59. Eustice DC, Feldman PA, Zajac I, Slee AM. Mechanism of action of DuP 721: Inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988;32:1218.
60. Tucker JA, Allwine DA, Grega KC, et al. Piperazinyl oxazolidenone antibacterial agents containing a pyridene diazene ortriazene heteroaromatic ring. J Med Chem 1998;41:3727-35.
61. Cantrell CL, Franzblau SG, Fischer NH. Antimycobacterial plant terpenoids. Planta Med. 2001;67:685-94.
62. Chumkaew P, Karalai C, Ponglimanont C, Chantrapromma K. Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum. J Nat Prod. 2003;66:540-3.
63. Wachter GA, Franzblau SG, Montenegro G et al. A new antitubercular mulinate diterpenoid from Azorella madreporic clos. J. Nat. Prod. l998;61:965-8.
64. Rodríguez AD, Ramírez C. Serrulatane diterpenes with antimycobacterial activity idolated from the west Indian sea whip Pseudopterogorgia elisabeathae. J Nat Prod. 2001;64:100-2.
65. Gundersen LL, Meyer JN, Spilsberg B. Synthesis and antimycobacterial activity of 6-aryl purines: The requirements for the N-9-substituted in active antimycobacterial purines. J Med Chem 2002;45:1383-6.
66. Scozzafava A, Mastrolorenzo A, Supuran CT. Antimycobacterial activity of 9-sulfonated/sulfenylated-6mercaptopurine derivatives. Bioorg Med Chem Lett 2001;11:1675-8.
67. Eratan M, Bilgin AA, Palaska E, Yulug N. Synthesis and antifungal activities of some 3-(2-phenylethyl)-5substituted-tetrahydro-2H-1,3,5- triiadiazine-2-thiones. Arzne Forsch/Drug Res 1992;42(1):160.
68. Katiyar D, Tiwari VK, Tripathi RP et al. Synthesis and antimycobacterial activity of 3,5-disubstituted thiadiazine thiones. Bioorg Med Chem 2003;11:4369-75.
69. Maddry JA, Bansal N, Bermudez LE, et al. Homologated aza analogs of arabinose as antimycobacterial agents. Bioorg Med Chem Lett 1998;8:237-342.
70. Tewari N, Tiwari VK, Tripathi RP, et al. Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents. Bio Med Chem Lett 2004;12:329-32.
71. Tripathi RR Tripathi R, Tiwari VK, et al. Synthesis of glycosylated β-amino acids as new class of antitubercular agents. Eur J Med Chem 2002;37:773-81.
72. Tewari N, Tiwari VK, Mishra RC, et al. Synthesis and bioevaluation of glycosyl ureas as α-glucosidase inhibitors and their effect on Mycobacterium. Bioorg Med Chem 2003;11:2911-22.
73. Ravin MT, Xu Z-Q, Rizzo JD, et al. US Pat. 6043271. Method for the preparation of (+/-)calanolide A and its intermediates. Chem Abs 1996;124:289113.
74. Flavin MT, Xu Z-Q, Rizzo JD, et al. Method for the preparation of (+)calanolide A and its analogs as HIV reverse transcriptase inhibitors. Chem Abstr 1998;129:216461.
75. Flavin MT, Xu H-Q, Rizzo JD, et al. Preparation of (+)-calanolide A and analogs. Sarwak Medichem pharmaceutical. Inc., USA. Chem Abstr 1999;130:281913.
76. Flavin M, Ze-Qi Xu. Preparation and antiviral activity of (+/-)-, (-)- and (+)calanolide A. Chem Abs 2000;132:222387.
77. Gerard J, Lioyd R, Barshy T, Haden P, Kelly MT, Andersen RJ, Massetoudes A-H. Antimycobacteual cyclic depsipeptides produced by two pseudomonads isolated from marine habitat. J Nat Prod 1997;60:223-9.
78. Hamann MT, Scheuer PJ, Kahalalide F. A bioactive depsipeptide from the sacoglossan mollusk Elysea rufescens and green alga bryopsis sp. J Am Chem Soc 1993;115:5825-6.
79. Hamann MT, Oho CS, Scheuer PJ, Dunbar DC, Kahalalide F. Elysea rufescens and its algal diet brypsis sp. J Org Chem 1996;61:6594-600.
80. Guchi KI, Saitoh S, Yamata Y. Novel 19-oxygenated sterols from the okinawan soft coral Litophytom Viridis. Chem Pharm Bull 1989;37:2553-4.